for people ages 18 years and up (full criteria)
study started
completion around
Principal Investigator
by Gary Schiller (ucla)



The study is a multicenter, open label Phase I/II trial.

  1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion)
  2. To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)

Official Title

A Phase I/II Study of Venetoclax and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML


The study is a multicenter, open label Phase I and Phase II trial combining lintuzumab-Ac225 with venetoclax in patients who have relapsed or refractory AML.

The Phase I portion is a dose-finding study which will enroll at least three patients at each dose level. Patients in a dose level will be observed for a minimum of 4 weeks before dose escalation occurs. There is no dose escalation for any individual patient.

The Phase II portion of the study will enroll patients at the MTD dose level of lintuzumab-Ac225 as determined in the Phase I portion of the study. The goal of the Phase II portion will be to further characterize the safety and efficacy of the MTD dose of lintuzumab-Ac225.


Acute Myeloid Leukemia, Relapsed Adult AML, Lintuzumab-Ac225, Venetoclax, Lintuzumab, Refractory AML, Spironolactone


You can join if…

Open to people ages 18 years and up

  1. Refractory or relapsed AML which will include:
    1. Refractory disease will be defined as at least 1 prior treatment with no remission.
    2. Relapsed disease will be defined as 5% or more blasts in bone marrow seen after remission.
    3. Patients with AML arising from myelodysplastic syndromes (including CMML) or myeloproliferative neoplasms (secondary AML, ts-AML) are also eligible.
  2. Circulating blast count ≤ 200/μL within 10 days prior to first cycle of treatment. Hydroxyurea should be used to keep the peripheral blast count ≤ 200/μL until the first day of protocol treatment, to the extent that this is possible
  3. ECOG ≤ 2
  4. Estimated creatinine clearance ≥ 50 mL/min
  5. AST and ALT ≤ 3.0 x ULN
  6. Bilirubin ≤ 3.0 x ULN

You CAN'T join if...

  1. Active CNS Leukemia.
  2. Known HIV infection or known hepatitis B or hepatitis C infection (with a detectable viral load).
  3. Participant has received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment.
  4. Secondary refractory AML (e.g., treated for current relapse without achieving remission);
    1. With the exception that single agent FLT3 inhibitors, IDH1/IDH2 inhibitors are allowed for current relapse without achieving remission.
  5. Have received prior radiation to maximally tolerated levels to any critical normal organ.
  6. Clinically significant cardiac disease.
  7. Active, uncontrolled serious infection.
  8. Have other non-myeloid malignancy within 2 years of entry (with exceptions).
  9. Psychiatric disorder that would preclude study participation

    10. Previous solid organ transplant (prior treatment with SCT is allowed but not if

    patient has GVHD or is still receiving immunosuppression/GVHD therapy).


  • University of California accepting new patients
    Los Angeles California 90095 United States
  • Fred Hutchinson Cancer Research Center accepting new patients
    Seattle Washington 98109 United States

Lead Scientist at University of California Health

  • Gary Schiller (ucla)
    Professor-in-Residence, Medicine. Authored (or co-authored) 154 research publications


accepting new patients
Start Date
Completion Date
Actinium Pharmaceuticals
Phase 1/2 research study
Study Type
Expecting 38 study participants
Last Updated